Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

193 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Gene expression analysis of TIL rich HPV-driven head and neck tumors reveals a distinct B-cell signature when compared to HPV independent tumors.
Wood O, Woo J, Seumois G, Savelyeva N, McCann KJ, Singh D, Jones T, Peel L, Breen MS, Ward M, Garrido Martin E, Sanchez-Elsner T, Thomas G, Vijayanand P, Woelk CH, King E, Ottensmeier C; SPARC Consortium. Wood O, et al. Among authors: ottensmeier c. Oncotarget. 2016 Aug 30;7(35):56781-56797. doi: 10.18632/oncotarget.10788. Oncotarget. 2016. PMID: 27462861 Free PMC article.
Tissue-resident memory features are linked to the magnitude of cytotoxic T cell responses in human lung cancer.
Ganesan AP, Clarke J, Wood O, Garrido-Martin EM, Chee SJ, Mellows T, Samaniego-Castruita D, Singh D, Seumois G, Alzetani A, Woo E, Friedmann PS, King EV, Thomas GJ, Sanchez-Elsner T, Vijayanand P, Ottensmeier CH. Ganesan AP, et al. Among authors: ottensmeier ch. Nat Immunol. 2017 Aug;18(8):940-950. doi: 10.1038/ni.3775. Epub 2017 Jun 19. Nat Immunol. 2017. PMID: 28628092 Free PMC article.
Targeting the Myofibroblastic Cancer-Associated Fibroblast Phenotype Through Inhibition of NOX4.
Hanley CJ, Mellone M, Ford K, Thirdborough SM, Mellows T, Frampton SJ, Smith DM, Harden E, Szyndralewiez C, Bullock M, Noble F, Moutasim KA, King EV, Vijayanand P, Mirnezami AH, Underwood TJ, Ottensmeier CH, Thomas GJ. Hanley CJ, et al. Among authors: ottensmeier ch. J Natl Cancer Inst. 2018 Jan 1;110(1):109-20. doi: 10.1093/jnci/djx121. J Natl Cancer Inst. 2018. PMID: 28922779 Free PMC article.
Recurrent group A Streptococcus tonsillitis is an immunosusceptibility disease involving antibody deficiency and aberrant TFH cells.
Dan JM, Havenar-Daughton C, Kendric K, Al-Kolla R, Kaushik K, Rosales SL, Anderson EL, LaRock CN, Vijayanand P, Seumois G, Layfield D, Cutress RI, Ottensmeier CH, Lindestam Arlehamn CS, Sette A, Nizet V, Bothwell M, Brigger M, Crotty S. Dan JM, et al. Among authors: ottensmeier ch. Sci Transl Med. 2019 Feb 6;11(478):eaau3776. doi: 10.1126/scitranslmed.aau3776. Sci Transl Med. 2019. PMID: 30728285 Free PMC article.
Single-cell transcriptomic analysis of tissue-resident memory T cells in human lung cancer.
Clarke J, Panwar B, Madrigal A, Singh D, Gujar R, Wood O, Chee SJ, Eschweiler S, King EV, Awad AS, Hanley CJ, McCann KJ, Bhattacharyya S, Woo E, Alzetani A, Seumois G, Thomas GJ, Ganesan AP, Friedmann PS, Sanchez-Elsner T, Ay F, Ottensmeier CH, Vijayanand P. Clarke J, et al. Among authors: ottensmeier ch. J Exp Med. 2019 Sep 2;216(9):2128-2149. doi: 10.1084/jem.20190249. Epub 2019 Jun 21. J Exp Med. 2019. PMID: 31227543 Free PMC article.
NOX4 Inhibition Potentiates Immunotherapy by Overcoming Cancer-Associated Fibroblast-Mediated CD8 T-cell Exclusion from Tumors.
Ford K, Hanley CJ, Mellone M, Szyndralewiez C, Heitz F, Wiesel P, Wood O, Machado M, Lopez MA, Ganesan AP, Wang C, Chakravarthy A, Fenton TR, King EV, Vijayanand P, Ottensmeier CH, Al-Shamkhani A, Savelyeva N, Thomas GJ. Ford K, et al. Among authors: ottensmeier ch. Cancer Res. 2020 May 1;80(9):1846-1860. doi: 10.1158/0008-5472.CAN-19-3158. Epub 2020 Mar 2. Cancer Res. 2020. PMID: 32122909 Free PMC article.
Single-cell transcriptomic analysis of SARS-CoV-2 reactive CD4 + T cells.
Meckiff BJ, Ramírez-Suástegui C, Fajardo V, Chee SJ, Kusnadi A, Simon H, Grifoni A, Pelosi E, Weiskopf D, Sette A, Ay F, Seumois G, Ottensmeier CH, Vijayanand P. Meckiff BJ, et al. Among authors: ottensmeier ch. bioRxiv [Preprint]. 2020 Jun 13:2020.06.12.148916. doi: 10.1101/2020.06.12.148916. bioRxiv. 2020. Update in: Cell. 2020 Nov 25;183(5):1340-1353.e16. doi: 10.1016/j.cell.2020.10.001. PMID: 32587963 Free PMC article. Updated. Preprint.
Severely ill COVID-19 patients display augmented functional properties in SARS-CoV-2-reactive CD8 + T cells.
Kusnadi A, Ramírez-Suástegui C, Fajardo V, Chee SJ, Meckiff BJ, Simon H, Pelosi E, Seumois G, Ay F, Vijayanand P, Ottensmeier CH. Kusnadi A, et al. Among authors: ottensmeier ch. bioRxiv [Preprint]. 2020 Jul 10:2020.07.09.194027. doi: 10.1101/2020.07.09.194027. bioRxiv. 2020. Update in: Sci Immunol. 2021 Jan 21;6(55):eabe4782. doi: 10.1126/sciimmunol.abe4782. PMID: 32676602 Free PMC article. Updated. Preprint.
M1hot tumor-associated macrophages boost tissue-resident memory T cells infiltration and survival in human lung cancer.
Garrido-Martin EM, Mellows TWP, Clarke J, Ganesan AP, Wood O, Cazaly A, Seumois G, Chee SJ, Alzetani A, King EV, Hedrick CC, Thomas G, Friedmann PS, Ottensmeier CH, Vijayanand P, Sanchez-Elsner T. Garrido-Martin EM, et al. Among authors: ottensmeier ch. J Immunother Cancer. 2020 Jul;8(2):e000778. doi: 10.1136/jitc-2020-000778. J Immunother Cancer. 2020. PMID: 32699181 Free PMC article.
Single-Cell Transcriptomic Analysis of SARS-CoV-2 Reactive CD4 + T Cells.
Meckiff BJ, Ramírez-Suástegui C, Fajardo V, Chee SJ, Kusnadi A, Simon H, Grifoni A, Pelosi E, Weiskopf D, Sette A, Ay F, Seumois G, Ottensmeier CH, Vijayanand P. Meckiff BJ, et al. Among authors: ottensmeier ch. SSRN [Preprint]. 2020 Jul 7:3641939. doi: 10.2139/ssrn.3641939. SSRN. 2020. Update in: Cell. 2020 Nov 25;183(5):1340-1353.e16. doi: 10.1016/j.cell.2020.10.001. PMID: 32742242 Free PMC article. Updated. Preprint.
Imbalance of Regulatory and Cytotoxic SARS-CoV-2-Reactive CD4+ T Cells in COVID-19.
Meckiff BJ, Ramírez-Suástegui C, Fajardo V, Chee SJ, Kusnadi A, Simon H, Eschweiler S, Grifoni A, Pelosi E, Weiskopf D, Sette A, Ay F, Seumois G, Ottensmeier CH, Vijayanand P. Meckiff BJ, et al. Among authors: ottensmeier ch. Cell. 2020 Nov 25;183(5):1340-1353.e16. doi: 10.1016/j.cell.2020.10.001. Epub 2020 Oct 5. Cell. 2020. PMID: 33096020 Free PMC article.
COVID-19 genetic risk variants are associated with expression of multiple genes in diverse immune cell types.
Schmiedel BJ, Chandra V, Rocha J, Gonzalez-Colin C, Bhattacharyya S, Madrigal A, Ottensmeier CH, Ay F, Vijayanand P. Schmiedel BJ, et al. Among authors: ottensmeier ch. bioRxiv [Preprint]. 2020 Dec 2:2020.12.01.407429. doi: 10.1101/2020.12.01.407429. bioRxiv. 2020. Update in: Nat Commun. 2021 Nov 19;12(1):6760. doi: 10.1038/s41467-021-26888-3. PMID: 33299987 Free PMC article. Updated. Preprint.
Intratumoral follicular regulatory T cells curtail anti-PD-1 treatment efficacy.
Eschweiler S, Clarke J, Ramírez-Suástegui C, Panwar B, Madrigal A, Chee SJ, Karydis I, Woo E, Alzetani A, Elsheikh S, Hanley CJ, Thomas GJ, Friedmann PS, Sanchez-Elsner T, Ay F, Ottensmeier CH, Vijayanand P. Eschweiler S, et al. Among authors: ottensmeier ch. Nat Immunol. 2021 Aug;22(8):1052-1063. doi: 10.1038/s41590-021-00958-6. Epub 2021 Jun 24. Nat Immunol. 2021. PMID: 34168370 Free PMC article.
Targeting the tumor mutanome for personalized vaccination in a TMB low non-small cell lung cancer.
McCann K, von Witzleben A, Thomas J, Wang C, Wood O, Singh D, Boukas K, Bendjama K, Silvestre N, Nielsen FC, Thomas G, Sanchez-Elsner T, Greenbaum J, Schoenberger S, Peters B, Vijayanand P, Savelyeva N, Ottensmeier C. McCann K, et al. J Immunother Cancer. 2022 Mar;10(3):e003821. doi: 10.1136/jitc-2021-003821. J Immunother Cancer. 2022. PMID: 35361728 Free PMC article.
Intermittent PI3Kδ inhibition sustains anti-tumour immunity and curbs irAEs.
Eschweiler S, Ramírez-Suástegui C, Li Y, King E, Chudley L, Thomas J, Wood O, von Witzleben A, Jeffrey D, McCann K, Simon H, Mondal M, Wang A, Dicker M, Lopez-Guadamillas E, Chou TF, Dobbs NA, Essame L, Acton G, Kelly F, Halbert G, Sacco JJ, Schache AG, Shaw R, McCaul JA, Paterson C, Davies JH, Brennan PA, Singh RP, Loadman PM, Wilson W, Hackshaw A, Seumois G, Okkenhaug K, Thomas GJ, Jones TM, Ay F, Friberg G, Kronenberg M, Vanhaesebroeck B, Vijayanand P, Ottensmeier CH. Eschweiler S, et al. Among authors: ottensmeier ch. Nature. 2022 May;605(7911):741-746. doi: 10.1038/s41586-022-04685-2. Epub 2022 May 4. Nature. 2022. PMID: 35508656 Free PMC article. Clinical Trial.
Single-cell immune profiling reveals long-term changes in myeloid cells and identifies a novel subset of CD9+ monocytes associated with COVID-19 hospitalization.
Pandori WJ, Padgett LE, Alimadadi A, Gutierrez NA, Araujo DJ, Huh CJ, Olingy CE, Dinh HQ, Wu R, Vijayanand P, Chee SJ, Ottensmeier CH, Hedrick CC. Pandori WJ, et al. Among authors: ottensmeier ch. J Leukoc Biol. 2022 Nov;112(5):1053-1063. doi: 10.1002/JLB.4COVA0122-076R. Epub 2022 Jul 22. J Leukoc Biol. 2022. PMID: 35866369 Free PMC article.
JAML immunotherapy targets recently activated tumor-infiltrating CD8+ T cells.
Eschweiler S, Wang A, Ramírez-Suástegui C, von Witzleben A, Li Y, Chee SJ, Simon H, Mondal M, Ellis M, Thomas GJ, Chandra V, Ottensmeier CH, Vijayanand P. Eschweiler S, et al. Among authors: ottensmeier ch. Cell Rep. 2023 Feb 28;42(2):112040. doi: 10.1016/j.celrep.2023.112040. Epub 2023 Jan 25. Cell Rep. 2023. PMID: 36701231 Free PMC article.
Transcriptomes and metabolism define mouse and human MAIT cell populations.
Chandra S, Ascui G, Riffelmacher T, Chawla A, Ramírez-Suástegui C, Castelan VC, Seumois G, Simon H, Murray MP, Seo GY, Premlal ALR, Schmiedel B, Verstichel G, Li Y, Lin CH, Greenbaum J, Lamberti J, Murthy R, Nigro J, Cheroutre H, Ottensmeier CH, Hedrick SM, Lu LF, Vijayanand P, Kronenberg M. Chandra S, et al. Among authors: ottensmeier ch. Sci Immunol. 2023 Nov 10;8(89):eabn8531. doi: 10.1126/sciimmunol.abn8531. Epub 2023 Nov 10. Sci Immunol. 2023. PMID: 37948512 Free PMC article.
Human CD79b+ neutrophils in the blood are associated with early-stage melanoma.
Meyer MA, Dinh HQ, Alimadadi A, Araujo DJ, Chatterjee N, Gutierrez NA, Zhu YP, Hunter EL, Liang S, Seumois G, Kiosses WB, Catz SD, Vijayanand P, Ottensmeier C, Hedrick CC. Meyer MA, et al. Front Immunol. 2023 Oct 31;14:1224045. doi: 10.3389/fimmu.2023.1224045. eCollection 2023. Front Immunol. 2023. PMID: 38022639 Free PMC article.
GPR25 promotes the formation of lung and liver tissue-resident memory CD8 T cells.
Feng H, Park S, Shin JW, Castañeda-Castro FE, Hernandez JR, Schmiedel BJ, Liu C, Jackson MR, Ottensmeier CH, Vijayanand P. Feng H, et al. Among authors: ottensmeier ch. Sci Immunol. 2025 Nov 21;10(113):eadu2089. doi: 10.1126/sciimmunol.adu2089. Epub 2025 Nov 21. Sci Immunol. 2025. PMID: 41270189 Free PMC article.
Induction of fibroblast senescence generates a non-fibrogenic myofibroblast phenotype that differentially impacts on cancer prognosis.
Mellone M, Hanley CJ, Thirdborough S, Mellows T, Garcia E, Woo J, Tod J, Frampton S, Jenei V, Moutasim KA, Kabir TD, Brennan PA, Venturi G, Ford K, Herranz N, Lim KP, Clarke J, Lambert DW, Prime SS, Underwood TJ, Vijayanand P, Eliceiri KW, Woelk C, King EV, Gil J, Ottensmeier CH, Thomas GJ. Mellone M, et al. Among authors: ottensmeier ch. Aging (Albany NY). 2016 Dec 15;9(1):114-132. doi: 10.18632/aging.101127. Aging (Albany NY). 2016. PMID: 27992856 Free PMC article.
Actively personalized vaccination trial for newly diagnosed glioblastoma.
Hilf N, Kuttruff-Coqui S, Frenzel K, Bukur V, Stevanović S, Gouttefangeas C, Platten M, Tabatabai G, Dutoit V, van der Burg SH, Thor Straten P, Martínez-Ricarte F, Ponsati B, Okada H, Lassen U, Admon A, Ottensmeier CH, Ulges A, Kreiter S, von Deimling A, Skardelly M, Migliorini D, Kroep JR, Idorn M, Rodon J, Piró J, Poulsen HS, Shraibman B, McCann K, Mendrzyk R, Löwer M, Stieglbauer M, Britten CM, Capper D, Welters MJP, Sahuquillo J, Kiesel K, Derhovanessian E, Rusch E, Bunse L, Song C, Heesch S, Wagner C, Kemmer-Brück A, Ludwig J, Castle JC, Schoor O, Tadmor AD, Green E, Fritsche J, Meyer M, Pawlowski N, Dorner S, Hoffgaard F, Rössler B, Maurer D, Weinschenk T, Reinhardt C, Huber C, Rammensee HG, Singh-Jasuja H, Sahin U, Dietrich PY, Wick W. Hilf N, et al. Among authors: ottensmeier ch. Nature. 2019 Jan;565(7738):240-245. doi: 10.1038/s41586-018-0810-y. Epub 2018 Dec 19. Nature. 2019. PMID: 30568303 Clinical Trial.
Neoantigen-directed immune escape in lung cancer evolution.
Rosenthal R, Cadieux EL, Salgado R, Bakir MA, Moore DA, Hiley CT, Lund T, Tanić M, Reading JL, Joshi K, Henry JY, Ghorani E, Wilson GA, Birkbak NJ, Jamal-Hanjani M, Veeriah S, Szallasi Z, Loi S, Hellmann MD, Feber A, Chain B, Herrero J, Quezada SA, Demeulemeester J, Van Loo P, Beck S, McGranahan N, Swanton C; TRACERx consortium. Rosenthal R, et al. Nature. 2019 Mar;567(7749):479-485. doi: 10.1038/s41586-019-1032-7. Epub 2019 Mar 20. Nature. 2019. PMID: 30894752 Free PMC article.
A clonal expression biomarker associates with lung cancer mortality.
Biswas D, Birkbak NJ, Rosenthal R, Hiley CT, Lim EL, Papp K, Boeing S, Krzystanek M, Djureinovic D, La Fleur L, Greco M, Döme B, Fillinger J, Brunnström H, Wu Y, Moore DA, Skrzypski M, Abbosh C, Litchfield K, Al Bakir M, Watkins TBK, Veeriah S, Wilson GA, Jamal-Hanjani M, Moldvay J, Botling J, Chinnaiyan AM, Micke P, Hackshaw A, Bartek J, Csabai I, Szallasi Z, Herrero J, McGranahan N, Swanton C; TRACERx Consortium. Biswas D, et al. Nat Med. 2019 Oct;25(10):1540-1548. doi: 10.1038/s41591-019-0595-z. Epub 2019 Oct 7. Nat Med. 2019. PMID: 31591602 Free PMC article.
Constitutive inflammation and epithelial-mesenchymal transition dictate sensitivity to nivolumab in CONFIRM: a placebo-controlled, randomised phase III trial.
Fennell DA, Hill K, Zhang M, Poile C, Ewings S, Baitei EY, Dzialo J, Nusrat N, Rogel J, Faulkner D, Ottensmeier C, Califano R, Hanna GG, Danson S, Steele N, Nye M, Johnson L, Mallard K, Lord J, Middleton C, Szlosarek P, Chan S, Darlison L, Wells-Jordan P, Richards C, Harber J, Bzura A, Spicer J, Pritchard C, Kamata T, Hahne JC, Jama M, Hollox EJ, Lester JF, Luo JL, Zhou Z, Yang H, Zhou H, Klampatsa A, Griffiths GO. Fennell DA, et al. Nat Commun. 2025 Jul 21;16(1):6688. doi: 10.1038/s41467-025-61691-4. Nat Commun. 2025. PMID: 40691143 Free PMC article. Clinical Trial.
Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution.
Abbosh C, Birkbak NJ, Wilson GA, Jamal-Hanjani M, Constantin T, Salari R, Le Quesne J, Moore DA, Veeriah S, Rosenthal R, Marafioti T, Kirkizlar E, Watkins TBK, McGranahan N, Ward S, Martinson L, Riley J, Fraioli F, Al Bakir M, Grönroos E, Zambrana F, Endozo R, Bi WL, Fennessy FM, Sponer N, Johnson D, Laycock J, Shafi S, Czyzewska-Khan J, Rowan A, Chambers T, Matthews N, Turajlic S, Hiley C, Lee SM, Forster MD, Ahmad T, Falzon M, Borg E, Lawrence D, Hayward M, Kolvekar S, Panagiotopoulos N, Janes SM, Thakrar R, Ahmed A, Blackhall F, Summers Y, Hafez D, Naik A, Ganguly A, Kareht S, Shah R, Joseph L, Marie Quinn A, Crosbie PA, Naidu B, Middleton G, Langman G, Trotter S, Nicolson M, Remmen H, Kerr K, Chetty M, Gomersall L, Fennell DA, Nakas A, Rathinam S, Anand G, Khan S, Russell P, Ezhil V, Ismail B, Irvin-Sellers M, Prakash V, Lester JF, Kornaszewska M, Attanoos R, Adams H, Davies H, Oukrif D, Akarca AU, Hartley JA, Lowe HL, Lock S, Iles N, Bell H, Ngai Y, Elgar G, Szallasi Z, Schwarz RF, Herrero J, Stewart A, Quezada SA, Peggs KS, Van Loo P, Dive C, Lin CJ, Rabinowitz M, Aerts HJWL, Hackshaw A, Shaw JA, Zimmermann BG; TRACERx consortium; PEACE consortium; Swanton C. Abbosh C, et al. Nature. 2017 Apr 26;545(7655):446-451. doi: 10.1038/nature22364. Nature. 2017. PMID: 28445469 Free PMC article.
Spatial heterogeneity of the T cell receptor repertoire reflects the mutational landscape in lung cancer.
Joshi K, de Massy MR, Ismail M, Reading JL, Uddin I, Woolston A, Hatipoglu E, Oakes T, Rosenthal R, Peacock T, Ronel T, Noursadeghi M, Turati V, Furness AJS, Georgiou A, Wong YNS, Ben Aissa A, Sunderland MW, Jamal-Hanjani M, Veeriah S, Birkbak NJ, Wilson GA, Hiley CT, Ghorani E, Guerra-Assunção JA, Herrero J, Enver T, Hadrup SR, Hackshaw A, Peggs KS, McGranahan N, Swanton C; TRACERx consortium; Quezada SA, Chain B. Joshi K, et al. Nat Med. 2019 Oct;25(10):1549-1559. doi: 10.1038/s41591-019-0592-2. Epub 2019 Oct 7. Nat Med. 2019. PMID: 31591606 Free PMC article.
Using DNA sequencing data to quantify T cell fraction and therapy response.
Bentham R, Litchfield K, Watkins TBK, Lim EL, Rosenthal R, Martínez-Ruiz C, Hiley CT, Bakir MA, Salgado R, Moore DA, Jamal-Hanjani M; TRACERx Consortium; Swanton C, McGranahan N. Bentham R, et al. Nature. 2021 Sep;597(7877):555-560. doi: 10.1038/s41586-021-03894-5. Epub 2021 Sep 8. Nature. 2021. PMID: 34497419
DNA vaccines to attack cancer.
Stevenson FK, Ottensmeier CH, Johnson P, Zhu D, Buchan SL, McCann KJ, Roddick JS, King AT, McNicholl F, Savelyeva N, Rice J. Stevenson FK, et al. Among authors: ottensmeier ch. Proc Natl Acad Sci U S A. 2004 Oct 5;101 Suppl 2(Suppl 2):14646-52. doi: 10.1073/pnas.0404896101. Epub 2004 Aug 3. Proc Natl Acad Sci U S A. 2004. PMID: 15292504 Free PMC article. Review.
Idiotype gene rescue in follicular lymphoma.
McCann K, Sahota SS, Stevenson FK, Ottensmeier CH. McCann K, et al. Among authors: ottensmeier ch. Methods Mol Med. 2005;115:145-71. doi: 10.1385/1-59259-936-2:145. Methods Mol Med. 2005. PMID: 15998967
DNA fusion-gene vaccination in patients with prostate cancer induces high-frequency CD8(+) T-cell responses and increases PSA doubling time.
Chudley L, McCann K, Mander A, Tjelle T, Campos-Perez J, Godeseth R, Creak A, Dobbyn J, Johnson B, Bass P, Heath C, Kerr P, Mathiesen I, Dearnaley D, Stevenson F, Ottensmeier C. Chudley L, et al. Cancer Immunol Immunother. 2012 Nov;61(11):2161-70. doi: 10.1007/s00262-012-1270-0. Epub 2012 May 22. Cancer Immunol Immunother. 2012. PMID: 22729556 Free PMC article. Clinical Trial.
The immune response in HPV+ oropharyngeal cancer.
King EV, Ottensmeier CH, Thomas GJ. King EV, et al. Among authors: ottensmeier ch. Oncoimmunology. 2014 Jan 1;3(1):e27254. doi: 10.4161/onci.27254. Oncoimmunology. 2014. PMID: 24575385 Free PMC article.
Idiotypic DNA vaccination for the treatment of multiple myeloma: safety and immunogenicity in a phase I clinical study.
McCann KJ, Godeseth R, Chudley L, Mander A, Di Genova G, Lloyd-Evans P, Kerr JP, Malykh VB, Jenner MW, Orchard KH, Stevenson FK, Ottensmeier CH. McCann KJ, et al. Among authors: ottensmeier ch. Cancer Immunol Immunother. 2015 Aug;64(8):1021-32. doi: 10.1007/s00262-015-1703-7. Epub 2015 May 16. Cancer Immunol Immunother. 2015. PMID: 25982371 Free PMC article. Clinical Trial.
Infliximab for IPILIMUMAB-Related Colitis-Letter.
Arriola E, Wheater M, Karydis I, Thomas G, Ottensmeier C. Arriola E, et al. Clin Cancer Res. 2015 Dec 15;21(24):5642-3. doi: 10.1158/1078-0432.CCR-15-2471. Clin Cancer Res. 2015. PMID: 26672088 No abstract available.
Tumour infiltrating lymphocytes correlate with improved survival in patients with oesophageal adenocarcinoma.
Noble F, Mellows T, McCormick Matthews LH, Bateman AC, Harris S, Underwood TJ, Byrne JP, Bailey IS, Sharland DM, Kelly JJ, Primrose JN, Sahota SS, Bateman AR, Thomas GJ, Ottensmeier CH. Noble F, et al. Among authors: ottensmeier ch. Cancer Immunol Immunother. 2016 Jun;65(6):651-62. doi: 10.1007/s00262-016-1826-5. Epub 2016 Mar 28. Cancer Immunol Immunother. 2016. PMID: 27020682 Free PMC article.
Targeting Carcinoembryonic Antigen with DNA Vaccination: On-Target Adverse Events Link with Immunologic and Clinical Outcomes.
McCann KJ, Mander A, Cazaly A, Chudley L, Stasakova J, Thirdborough S, King A, Lloyd-Evans P, Buxton E, Edwards C, Halford S, Bateman A, O'Callaghan A, Clive S, Anthoney A, Jodrell DI, Weinschenk T, Simon P, Sahin U, Thomas GJ, Stevenson FK, Ottensmeier CH. McCann KJ, et al. Among authors: ottensmeier ch. Clin Cancer Res. 2016 Oct 1;22(19):4827-4836. doi: 10.1158/1078-0432.CCR-15-2507. Epub 2016 Apr 18. Clin Cancer Res. 2016. PMID: 27091407 Free PMC article. Clinical Trial.
Fc-Optimized Anti-CD25 Depletes Tumor-Infiltrating Regulatory T Cells and Synergizes with PD-1 Blockade to Eradicate Established Tumors.
Arce Vargas F, Furness AJS, Solomon I, Joshi K, Mekkaoui L, Lesko MH, Miranda Rota E, Dahan R, Georgiou A, Sledzinska A, Ben Aissa A, Franz D, Werner Sunderland M, Wong YNS, Henry JY, O'Brien T, Nicol D, Challacombe B, Beers SA; Melanoma TRACERx Consortium; Renal TRACERx Consortium; Lung TRACERx Consortium; Turajlic S, Gore M, Larkin J, Swanton C, Chester KA, Pule M, Ravetch JV, Marafioti T, Peggs KS, Quezada SA. Arce Vargas F, et al. Immunity. 2017 Apr 18;46(4):577-586. doi: 10.1016/j.immuni.2017.03.013. Epub 2017 Apr 11. Immunity. 2017. PMID: 28410988 Free PMC article.
Tracking the Evolution of Non-Small-Cell Lung Cancer.
Jamal-Hanjani M, Wilson GA, McGranahan N, Birkbak NJ, Watkins TBK, Veeriah S, Shafi S, Johnson DH, Mitter R, Rosenthal R, Salm M, Horswell S, Escudero M, Matthews N, Rowan A, Chambers T, Moore DA, Turajlic S, Xu H, Lee SM, Forster MD, Ahmad T, Hiley CT, Abbosh C, Falzon M, Borg E, Marafioti T, Lawrence D, Hayward M, Kolvekar S, Panagiotopoulos N, Janes SM, Thakrar R, Ahmed A, Blackhall F, Summers Y, Shah R, Joseph L, Quinn AM, Crosbie PA, Naidu B, Middleton G, Langman G, Trotter S, Nicolson M, Remmen H, Kerr K, Chetty M, Gomersall L, Fennell DA, Nakas A, Rathinam S, Anand G, Khan S, Russell P, Ezhil V, Ismail B, Irvin-Sellers M, Prakash V, Lester JF, Kornaszewska M, Attanoos R, Adams H, Davies H, Dentro S, Taniere P, O'Sullivan B, Lowe HL, Hartley JA, Iles N, Bell H, Ngai Y, Shaw JA, Herrero J, Szallasi Z, Schwarz RF, Stewart A, Quezada SA, Le Quesne J, Van Loo P, Dive C, Hackshaw A, Swanton C; TRACERx Consortium. Jamal-Hanjani M, et al. N Engl J Med. 2017 Jun 1;376(22):2109-2121. doi: 10.1056/NEJMoa1616288. Epub 2017 Apr 26. N Engl J Med. 2017. PMID: 28445112 Free article.
Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies.
Arce Vargas F, Furness AJS, Litchfield K, Joshi K, Rosenthal R, Ghorani E, Solomon I, Lesko MH, Ruef N, Roddie C, Henry JY, Spain L, Ben Aissa A, Georgiou A, Wong YNS, Smith M, Strauss D, Hayes A, Nicol D, O'Brien T, Mårtensson L, Ljungars A, Teige I, Frendéus B; TRACERx Melanoma; TRACERx Renal; TRACERx Lung consortia; Pule M, Marafioti T, Gore M, Larkin J, Turajlic S, Swanton C, Peggs KS, Quezada SA. Arce Vargas F, et al. Cancer Cell. 2018 Apr 9;33(4):649-663.e4. doi: 10.1016/j.ccell.2018.02.010. Epub 2018 Mar 22. Cancer Cell. 2018. PMID: 29576375 Free PMC article.
Nanoscale dysregulation of collagen structure-function disrupts mechano-homeostasis and mediates pulmonary fibrosis.
Jones MG, Andriotis OG, Roberts JJ, Lunn K, Tear VJ, Cao L, Ask K, Smart DE, Bonfanti A, Johnson P, Alzetani A, Conforti F, Doherty R, Lai CY, Johnson B, Bourdakos KN, Fletcher SV, Marshall BG, Jogai S, Brereton CJ, Chee SJ, Ottensmeier CH, Sime P, Gauldie J, Kolb M, Mahajan S, Fabre A, Bhaskar A, Jarolimek W, Richeldi L, O'Reilly KM, Monk PD, Thurner PJ, Davies DE. Jones MG, et al. Among authors: ottensmeier ch. Elife. 2018 Jul 3;7:e36354. doi: 10.7554/eLife.36354. Elife. 2018. PMID: 29966587 Free PMC article.
Paracrine signalling during ZEB1-mediated epithelial-mesenchymal transition augments local myofibroblast differentiation in lung fibrosis.
Yao L, Conforti F, Hill C, Bell J, Drawater L, Li J, Liu D, Xiong H, Alzetani A, Chee SJ, Marshall BG, Fletcher SV, Hancock D, Coldwell M, Yuan X, Ottensmeier CH, Downward J, Collins JE, Ewing RM, Richeldi L, Skipp P, Jones MG, Davies DE, Wang Y. Yao L, et al. Among authors: ottensmeier ch. Cell Death Differ. 2019 May;26(5):943-957. doi: 10.1038/s41418-018-0175-7. Epub 2018 Jul 26. Cell Death Differ. 2019. PMID: 30050057 Free PMC article.
Importance of the immune system in head and neck cancer.
Mirza AH, Thomas G, Ottensmeier CH, King EV. Mirza AH, et al. Among authors: ottensmeier ch. Head Neck. 2019 Aug;41(8):2789-2800. doi: 10.1002/hed.25716. Epub 2019 Feb 28. Head Neck. 2019. PMID: 30821023 Review.
Autophagy inhibition-mediated epithelial-mesenchymal transition augments local myofibroblast differentiation in pulmonary fibrosis.
Hill C, Li J, Liu D, Conforti F, Brereton CJ, Yao L, Zhou Y, Alzetani A, Chee SJ, Marshall BG, Fletcher SV, Hancock D, Ottensmeier CH, Steele AJ, Downward J, Richeldi L, Lu X, Davies DE, Jones MG, Wang Y. Hill C, et al. Among authors: ottensmeier ch. Cell Death Dis. 2019 Aug 7;10(8):591. doi: 10.1038/s41419-019-1820-x. Cell Death Dis. 2019. PMID: 31391462 Free PMC article.
Geospatial immune variability illuminates differential evolution of lung adenocarcinoma.
AbdulJabbar K, Raza SEA, Rosenthal R, Jamal-Hanjani M, Veeriah S, Akarca A, Lund T, Moore DA, Salgado R, Al Bakir M, Zapata L, Hiley CT, Officer L, Sereno M, Smith CR, Loi S, Hackshaw A, Marafioti T, Quezada SA, McGranahan N, Le Quesne J; TRACERx Consortium; Swanton C, Yuan Y. AbdulJabbar K, et al. Nat Med. 2020 Jul;26(7):1054-1062. doi: 10.1038/s41591-020-0900-x. Epub 2020 May 27. Nat Med. 2020. PMID: 32461698 Free PMC article.
Publisher Correction: A clonal expression biomarker associates with lung cancer mortality.
Biswas D, Birkbak NJ, Rosenthal R, Hiley CT, Lim EL, Papp K, Boeing S, Krzystanek M, Djureinovic D, La Fleur L, Greco M, Döme B, Fillinger J, Brunnström H, Wu Y, Moore DA, Skrzypski M, Abbosh C, Litchfield K, Al Bakir M, Watkins TBK, Veeriah S, Wilson GA, Jamal-Hanjani M, Moldvay J, Botling J, Chinnaiyan AM, Micke P, Hackshaw A, Bartek J, Csabai I, Szallasi Z, Herrero J, McGranahan N, Swanton C; TRACERx Consortium. Biswas D, et al. Nat Med. 2020 Jul;26(7):1148. doi: 10.1038/s41591-020-0899-z. Nat Med. 2020. PMID: 32494065
The T cell differentiation landscape is shaped by tumour mutations in lung cancer.
Ghorani E, Reading JL, Henry JY, Massy MR, Rosenthal R, Turati V, Joshi K, Furness AJS, Ben Aissa A, Saini SK, Ramskov S, Georgiou A, Sunderland MW, Wong YNS, Mucha MV, Day W, Galvez-Cancino F, Becker PD, Uddin I, Oakes T, Ismail M, Ronel T, Woolston A, Jamal-Hanjani M, Veeriah S, Birkbak NJ, Wilson GA, Litchfield K, Conde L, Guerra-Assunção JA, Blighe K, Biswas D, Salgado R, Lund T, Bakir MA, Moore DA, Hiley CT, Loi S, Sun Y, Yuan Y, AbdulJabbar K, Turajilic S, Herrero J, Enver T, Hadrup SR, Hackshaw A, Peggs KS, McGranahan N, Chain B; TRACERx Consortium; Swanton C, Quezada SA. Ghorani E, et al. Nat Cancer. 2020 May;1(5):546-561. doi: 10.1038/s43018-020-0066-y. Epub 2020 May 22. Nat Cancer. 2020. PMID: 32803172 Free PMC article.
Novel players: tissue-resident memory B cells.
Savelyeva N, Ottensmeier CH. Savelyeva N, et al. Among authors: ottensmeier ch. Blood. 2020 Dec 10;136(24):2722-2723. doi: 10.1182/blood.2020007890. Blood. 2020. PMID: 33301032 Free article. No abstract available.
DNA Vaccines Targeting Novel Cancer-Associated Antigens Frequently Expressed in Head and Neck Cancer Enhance the Efficacy of Checkpoint Inhibitor.
Wang C, Zainal NS, Chai SJ, Dickie J, Gan CP, Zulaziz N, Lye BKW, Sutavani RV, Ottensmeier CH, King EV, Abraham MT, Ismail SMB, Lau SH, Kallarakkal TG, Mun KS, Zain RB, Abdul Rahman ZA, Thomas GJ, Cheong SC, Savelyeva N, Lim KP. Wang C, et al. Among authors: ottensmeier ch. Front Immunol. 2021 Oct 18;12:763086. doi: 10.3389/fimmu.2021.763086. eCollection 2021. Front Immunol. 2021. PMID: 34733290 Free PMC article.
HIF activation enhances FcγRIIb expression on mononuclear phagocytes impeding tumor targeting antibody immunotherapy.
Hussain K, Liu R, Smith RCG, Müller KTJ, Ghorbani M, Macari S, Cleary KLS, Oldham RJ, Foxall RB, James S, Booth SG, Murray T, Dahal LN, Hargreaves CE, Kemp RS, Longley J, Douglas J, Markham H, Chee SJ, Stopforth RJ, Roghanian A, Carter MJ, Ottensmeier CH, Frendéus B, Cutress RI, French RR, Glennie MJ, Strefford JC, Thirdborough SM, Beers SA, Cragg MS. Hussain K, et al. Among authors: ottensmeier ch. J Exp Clin Cancer Res. 2022 Apr 7;41(1):131. doi: 10.1186/s13046-022-02294-5. J Exp Clin Cancer Res. 2022. PMID: 35392965 Free PMC article.
A local human Vδ1 T cell population is associated with survival in nonsmall-cell lung cancer.
Wu Y, Biswas D, Usaite I, Angelova M, Boeing S, Karasaki T, Veeriah S, Czyzewska-Khan J, Morton C, Joseph M, Hessey S, Reading J, Georgiou A, Al-Bakir M; TRACERx Consortium; McGranahan N, Jamal-Hanjani M, Hackshaw A, Quezada SA, Hayday AC, Swanton C. Wu Y, et al. Nat Cancer. 2022 Jun;3(6):696-709. doi: 10.1038/s43018-022-00376-z. Epub 2022 May 30. Nat Cancer. 2022. PMID: 35637401 Free PMC article.
Synthesis and in vitro evaluation of alpha-GalCer epimers.
Trappeniers M, Goormans S, Van Beneden K, Decruy T, Linclau B, Al-Shamkhani A, Elliott T, Ottensmeier C, Werner JM, Elewaut D, Van Calenbergh S. Trappeniers M, et al. ChemMedChem. 2008 Jul;3(7):1061-70. doi: 10.1002/cmdc.200800021. ChemMedChem. 2008. PMID: 18418814
Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial.
Muers MF, Stephens RJ, Fisher P, Darlison L, Higgs CM, Lowry E, Nicholson AG, O'Brien M, Peake M, Rudd R, Snee M, Steele J, Girling DJ, Nankivell M, Pugh C, Parmar MK; MS01 Trial Management Group. Muers MF, et al. Lancet. 2008 May 17;371(9625):1685-94. doi: 10.1016/S0140-6736(08)60727-8. Lancet. 2008. PMID: 18486741 Free PMC article. Clinical Trial.
Synthesis and in vivo evaluation of 4-deoxy-4,4-difluoro-KRN7000.
Leung L, Tomassi C, Van Beneden K, Decruy T, Elewaut D, Elliott T, Al-Shamkhani A, Ottensmeier C, Van Calenbergh S, Werner J, Williams T, Linclau B. Leung L, et al. Org Lett. 2008 Oct 16;10(20):4433-6. doi: 10.1021/ol801663m. Epub 2008 Sep 18. Org Lett. 2008. PMID: 18798635
The synthesis and in vivo evaluation of 2',2'-difluoro KRN7000.
Leung L, Tomassi C, Van Beneden K, Decruy T, Trappeniers M, Elewaut D, Gao Y, Elliott T, Al-Shamkhani A, Ottensmeier C, Werner JM, Williams A, Van Calenbergh S, Linclau B. Leung L, et al. ChemMedChem. 2009 Mar;4(3):329-34. doi: 10.1002/cmdc.200800348. ChemMedChem. 2009. PMID: 19137519
DNA vaccines against cancer come of age.
Stevenson FK, Ottensmeier CH, Rice J. Stevenson FK, et al. Among authors: ottensmeier ch. Curr Opin Immunol. 2010 Apr;22(2):264-70. doi: 10.1016/j.coi.2010.01.019. Epub 2010 Feb 19. Curr Opin Immunol. 2010. PMID: 20172703 Review.
Ig gene diversification and selection in follicular lymphoma, diffuse large B cell lymphoma and primary central nervous system lymphoma revealed by lineage tree and mutation analyses.
Zuckerman NS, McCann KJ, Ottensmeier CH, Barak M, Shahaf G, Edelman H, Dunn-Walters D, Abraham RS, Stevenson FK, Mehr R. Zuckerman NS, et al. Among authors: ottensmeier ch. Int Immunol. 2010 Nov;22(11):875-87. doi: 10.1093/intimm/dxq441. Epub 2010 Nov 8. Int Immunol. 2010. PMID: 21059768
A phase I/II, multiple-dose, dose-escalation study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with advanced solid tumors.
Angevin E, Tabernero J, Elez E, Cohen SJ, Bahleda R, van Laethem JL, Ottensmeier C, Lopez-Martin JA, Clive S, Joly F, Ray-Coquard I, Dirix L, Machiels JP, Steven N, Reddy M, Hall B, Puchalski TA, Bandekar R, van de Velde H, Tromp B, Vermeulen J, Kurzrock R. Angevin E, et al. Clin Cancer Res. 2014 Apr 15;20(8):2192-204. doi: 10.1158/1078-0432.CCR-13-2200. Epub 2014 Feb 21. Clin Cancer Res. 2014. PMID: 24563479 Clinical Trial.
NY-ESO-1 specific antibody and cellular responses in melanoma patients primed with NY-ESO-1 protein in ISCOMATRIX and boosted with recombinant NY-ESO-1 fowlpox virus.
Chen JL, Dawoodji A, Tarlton A, Gnjatic S, Tajar A, Karydis I, Browning J, Pratap S, Verfaille C, Venhaus RR, Pan L, Altman DG, Cebon JS, Old LL, Nathan P, Ottensmeier C, Middleton M, Cerundolo V. Chen JL, et al. Int J Cancer. 2015 Mar 15;136(6):E590-601. doi: 10.1002/ijc.29118. Epub 2014 Aug 14. Int J Cancer. 2015. PMID: 25081390 Clinical Trial.
Harmonisation of short-term in vitro culture for the expansion of antigen-specific CD8(+) T cells with detection by ELISPOT and HLA-multimer staining.
Chudley L, McCann KJ, Coleman A, Cazaly AM, Bidmon N, Britten CM, van der Burg SH, Gouttefangeas C, Jandus C, Laske K, Maurer D, Romero P, Schröder H, Stynenbosch LF, Walter S, Welters MJ, Ottensmeier CH. Chudley L, et al. Among authors: ottensmeier ch. Cancer Immunol Immunother. 2014 Nov;63(11):1199-211. doi: 10.1007/s00262-014-1593-0. Epub 2014 Aug 19. Cancer Immunol Immunother. 2014. PMID: 25134947 Free PMC article.
COAST (Cisplatin ototoxicity attenuated by aspirin trial): A phase II double-blind, randomised controlled trial to establish if aspirin reduces cisplatin induced hearing-loss.
Crabb SJ, Martin K, Abab J, Ratcliffe I, Thornton R, Lineton B, Ellis M, Moody R, Stanton L, Galanopoulou A, Maishman T, Geldart T, Bayne M, Davies J, Lamb C, Popat S, Joffe JK, Nutting C, Chester J, Hartley A, Thomas G, Ottensmeier C, Huddart R, King E. Crabb SJ, et al. Eur J Cancer. 2017 Dec;87:75-83. doi: 10.1016/j.ejca.2017.09.033. Epub 2017 Nov 10. Eur J Cancer. 2017. PMID: 29128692 Free PMC article. Clinical Trial.
Linear doggybone DNA vaccine induces similar immunological responses to conventional plasmid DNA independently of immune recognition by TLR9 in a pre-clinical model.
Allen A, Wang C, Caproni LJ, Sugiyarto G, Harden E, Douglas LR, Duriez PJ, Karbowniczek K, Extance J, Rothwell PJ, Orefo I, Tite JP, Stevenson FK, Ottensmeier CH, Savelyeva N. Allen A, et al. Among authors: ottensmeier ch. Cancer Immunol Immunother. 2018 Apr;67(4):627-638. doi: 10.1007/s00262-017-2111-y. Epub 2018 Jan 12. Cancer Immunol Immunother. 2018. PMID: 29330557 Free PMC article.
Pulmonary venous circulating tumor cell dissemination before tumor resection and disease relapse.
Chemi F, Rothwell DG, McGranahan N, Gulati S, Abbosh C, Pearce SP, Zhou C, Wilson GA, Jamal-Hanjani M, Birkbak N, Pierce J, Kim CS, Ferdous S, Burt DJ, Slane-Tan D, Gomes F, Moore D, Shah R, Al Bakir M, Hiley C, Veeriah S, Summers Y, Crosbie P, Ward S, Mesquita B, Dynowski M, Biswas D, Tugwood J, Blackhall F, Miller C, Hackshaw A, Brady G, Swanton C, Dive C; TRACERx Consortium. Chemi F, et al. Nat Med. 2019 Oct;25(10):1534-1539. doi: 10.1038/s41591-019-0593-1. Epub 2019 Oct 7. Nat Med. 2019. PMID: 31591595 Free PMC article.
Anti-PD-1 immunotherapy leads to tuberculosis reactivation via dysregulation of TNF-α.
Tezera LB, Bielecka MK, Ogongo P, Walker NF, Ellis M, Garay-Baquero DJ, Thomas K, Reichmann MT, Johnston DA, Wilkinson KA, Ahmed M, Jogai S, Jayasinghe SN, Wilkinson RJ, Mansour S, Thomas GJ, Ottensmeier CH, Leslie A, Elkington PT. Tezera LB, et al. Among authors: ottensmeier ch. Elife. 2020 Feb 24;9:e52668. doi: 10.7554/eLife.52668. Elife. 2020. PMID: 32091388 Free PMC article.
Results of a randomized, double-blind phase II clinical trial of NY-ESO-1 vaccine with ISCOMATRIX adjuvant versus ISCOMATRIX alone in participants with high-risk resected melanoma.
Cebon JS, Gore M, Thompson JF, Davis ID, McArthur GA, Walpole E, Smithers M, Cerundolo V, Dunbar PR, MacGregor D, Fisher C, Millward M, Nathan P, Findlay MPN, Hersey P, Evans TRJ, Ottensmeier CH, Marsden J, Dalgleish AG, Corrie PG, Maria M, Brimble M, Williams G, Winkler S, Jackson HM, Endo-Munoz L, Tutuka CSA, Venhaus R, Old LJ, Haack D, Maraskovsky E, Behren A, Chen W. Cebon JS, et al. Among authors: ottensmeier ch. J Immunother Cancer. 2020 Apr;8(1):e000410. doi: 10.1136/jitc-2019-000410. J Immunother Cancer. 2020. PMID: 32317292 Free PMC article. Clinical Trial.
HNSCC: Tumour Antigens and Their Targeting by Immunotherapy.
von Witzleben A, Wang C, Laban S, Savelyeva N, Ottensmeier CH. von Witzleben A, et al. Among authors: ottensmeier ch. Cells. 2020 Sep 15;9(9):2103. doi: 10.3390/cells9092103. Cells. 2020. PMID: 32942747 Free PMC article. Review.
The DANTE trial protocol: a randomised phase III trial to evaluate the Duration of ANti-PD-1 monoclonal antibody Treatment in patients with metastatic mElanoma.
Coen O, Corrie P, Marshall H, Plummer R, Ottensmeier C, Hook J, Bell S, Sagoo GS, Meads D, Bestall J, Velikova G, Gallagher FA, Smith A, Howard H, Mason E, Katona E, Silva S, Collinson M, Rodwell S, Danson S. Coen O, et al. BMC Cancer. 2021 Jul 1;21(1):761. doi: 10.1186/s12885-021-08509-w. BMC Cancer. 2021. PMID: 34210290 Free PMC article.
Anti-idiotype vaccines.
McCarthy H, Ottensmeier CH, Hamblin TJ, Stevenson FK. McCarthy H, et al. Among authors: ottensmeier ch. Br J Haematol. 2003 Dec;123(5):770-81. doi: 10.1046/j.1365-2141.2003.04698.x. Br J Haematol. 2003. PMID: 14632768 Review. No abstract available.
DNA fusion vaccines enter the clinic.
Stevenson FK, Mander A, Chudley L, Ottensmeier CH. Stevenson FK, et al. Among authors: ottensmeier ch. Cancer Immunol Immunother. 2011 Aug;60(8):1147-51. doi: 10.1007/s00262-011-1042-2. Epub 2011 Jun 5. Cancer Immunol Immunother. 2011. PMID: 21644035 Free PMC article. Review.
Harmonization of the intracellular cytokine staining assay.
Welters MJ, Gouttefangeas C, Ramwadhdoebe TH, Letsch A, Ottensmeier CH, Britten CM, van der Burg SH. Welters MJ, et al. Among authors: ottensmeier ch. Cancer Immunol Immunother. 2012 Jul;61(7):967-78. doi: 10.1007/s00262-012-1282-9. Epub 2012 May 22. Cancer Immunol Immunother. 2012. PMID: 22714399 Free PMC article.
Phase II study of first-line bortezomib and cisplatin in malignant pleural mesothelioma and prospective validation of progression free survival rate as a primary end-point for mesothelioma clinical trials (European Organisation for Research and Treatment of Cancer 08052).
O'Brien ME, Gaafar RM, Popat S, Grossi F, Price A, Talbot DC, Cufer T, Ottensmeier C, Danson S, Pallis A, Hasan B, Van Meerbeeck JP, Baas P. O'Brien ME, et al. Eur J Cancer. 2013 Sep;49(13):2815-22. doi: 10.1016/j.ejca.2013.05.008. Epub 2013 Jun 20. Eur J Cancer. 2013. PMID: 23791541 Clinical Trial.
Outcome and Biomarker Analysis from a Multicenter Phase 2 Study of Ipilimumab in Combination with Carboplatin and Etoposide as First-Line Therapy for Extensive-Stage SCLC.
Arriola E, Wheater M, Galea I, Cross N, Maishman T, Hamid D, Stanton L, Cave J, Geldart T, Mulatero C, Potter V, Danson S, Woll PJ, Griffiths R, Nolan L, Ottensmeier C. Arriola E, et al. J Thorac Oncol. 2016 Sep;11(9):1511-21. doi: 10.1016/j.jtho.2016.05.028. Epub 2016 Jun 11. J Thorac Oncol. 2016. PMID: 27296105 Free PMC article. Clinical Trial.
Human Papillomavirus Drives Tumor Development Throughout the Head and Neck: Improved Prognosis Is Associated With an Immune Response Largely Restricted to the Oropharynx.
Chakravarthy A, Henderson S, Thirdborough SM, Ottensmeier CH, Su X, Lechner M, Feber A, Thomas GJ, Fenton TR. Chakravarthy A, et al. Among authors: ottensmeier ch. J Clin Oncol. 2016 Dec;34(34):4132-4141. doi: 10.1200/JCO.2016.68.2955. Epub 2016 Oct 31. J Clin Oncol. 2016. PMID: 27863190 Free PMC article.
Multicenter, Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Pravastatin Added to First-Line Standard Chemotherapy in Small-Cell Lung Cancer (LUNGSTAR).
Seckl MJ, Ottensmeier CH, Cullen M, Schmid P, Ngai Y, Muthukumar D, Thompson J, Harden S, Middleton G, Fife KM, Crosse B, Taylor P, Nash S, Hackshaw A. Seckl MJ, et al. Among authors: ottensmeier ch. J Clin Oncol. 2017 May 10;35(14):1506-1514. doi: 10.1200/JCO.2016.69.7391. Epub 2017 Feb 27. J Clin Oncol. 2017. PMID: 28240967 Free PMC article. Clinical Trial.
Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution.
McGranahan N, Rosenthal R, Hiley CT, Rowan AJ, Watkins TBK, Wilson GA, Birkbak NJ, Veeriah S, Van Loo P, Herrero J, Swanton C; TRACERx Consortium. McGranahan N, et al. Cell. 2017 Nov 30;171(6):1259-1271.e11. doi: 10.1016/j.cell.2017.10.001. Epub 2017 Oct 26. Cell. 2017. PMID: 29107330 Free PMC article.
Targeting gp100 and TRP-2 with a DNA vaccine: Incorporating T cell epitopes with a human IgG1 antibody induces potent T cell responses that are associated with favourable clinical outcome in a phase I/II trial.
Patel PM, Ottensmeier CH, Mulatero C, Lorigan P, Plummer R, Pandha H, Elsheikh S, Hadjimichael E, Villasanti N, Adams SE, Cunnell M, Metheringham RL, Brentville VA, Machado L, Daniels I, Gijon M, Hannaman D, Durrant LG. Patel PM, et al. Among authors: ottensmeier ch. Oncoimmunology. 2018 Feb 22;7(6):e1433516. doi: 10.1080/2162402X.2018.1433516. eCollection 2018. Oncoimmunology. 2018. PMID: 29872563 Free PMC article.
Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial.
Corrie PG, Marshall A, Nathan PD, Lorigan P, Gore M, Tahir S, Faust G, Kelly CG, Marples M, Danson SJ, Marshall E, Houston SJ, Board RE, Waterston AM, Nobes JP, Harries M, Kumar S, Goodman A, Dalgleish A, Martin-Clavijo A, Westwell S, Casasola R, Chao D, Maraveyas A, Patel PM, Ottensmeier CH, Farrugia D, Humphreys A, Eccles B, Young G, Barker EO, Harman C, Weiss M, Myers KA, Chhabra A, Rodwell SH, Dunn JA, Middleton MR; AVAST-M Investigators; Nathan P, Lorigan P, Dziewulski P, Holikova S, Panwar U, Tahir S, Faust G, Thomas A, Corrie P, Sirohi B, Kelly C, Middleton M, Marples M, Danson S, Lester J, Marshall E, Ajaz M, Houston S, Board R, Eaton D, Waterston A, Nobes J, Loo S, Gray G, Stubbings H, Gore M, Harries M, Kumar S, Goodman A, Dalgleish A, Martin-Clavijo A, Marsden J, Westwell S, Casasola R, Chao D, Maraveyas A, Marshall E, Patel P, Ottensmeier C, Farrugia D, Humphreys A, Eccles B, Dega R, Herbert C, Price C, Brunt M, Scott-Brown M, Hamilton J, Hayward RL, Smyth J, Woodings P, Nayak N, Burrows L, Wolstenholme V, Wagstaff J, Nicolson M, Wilson A, Barlow C, Scrase C, Podd T, Gonzalez M, Stewart J, Highley M, Wolstenholme V, Grumett S, Goodman A, Talbot T, Nathan … See abstract for full author list ➔ Corrie PG, et al. Among authors: ottensmeier c, ottensmeier ch. Ann Oncol. 2018 Aug 1;29(8):1843-1852. doi: 10.1093/annonc/mdy229. Ann Oncol. 2018. PMID: 30010756 Free PMC article. Clinical Trial.
Publisher Correction: Actively personalized vaccination trial for newly diagnosed glioblastoma.
Hilf N, Kuttruff-Coqui S, Frenzel K, Bukur V, Stevanović S, Gouttefangeas C, Platten M, Tabatabai G, Dutoit V, van der Burg SH, Straten PT, Martinez-Ricarte F, Ponsati B, Okada H, Lassen U, Admon A, Ottensmeier CH, Ulges A, Kreiter S, von Deimling A, Skardelly M, Migliorini D, Kroep JR, Idorn M, Rodon J, Piro J, Poulsen HS, Shraibman B, McCann K, Mendrzyk R, Lower M, Stieglbauer M, Britten CM, Capper D, Welters MJP, Sahuquillo J, Kiesel K, Derhovanessian E, Rusch E, Bunse L, Song C, Heesch S, Wagner C, Kemmer-Bruck A, Ludwig J, Castle JC, Schoor O, Tadmor AD, Green E, Fritsche J, Meyer M, Pawlowski N, Dorner S, Hoffgaard F, Rossler B, Maurer D, Weinschenk T, Reinhardt C, Huber C, Rammensee HG, Singh-Jasuja H, Sahin U, Dietrich PY, Wick W. Hilf N, et al. Among authors: ottensmeier ch. Nature. 2019 Feb;566(7745):E13. doi: 10.1038/s41586-019-0959-z. Nature. 2019. PMID: 30733620
Representative Sequencing: Unbiased Sampling of Solid Tumor Tissue.
Litchfield K, Stanislaw S, Spain L, Gallegos LL, Rowan A, Schnidrig D, Rosenbaum H, Harle A, Au L, Hill SM, Tippu Z, Thomas J, Thompson L, Xu H, Horswell S, Barhoumi A, Jones C, Leith KF, Burgess DL, Watkins TBK, Lim E, Birkbak NJ, Lamy P, Nordentoft I, Dyrskjøt L, Pickering L, Hazell S, Jamal-Hanjani M; PEACE Consortium; Larkin J, Swanton C, Alexander NR, Turajlic S. Litchfield K, et al. Cell Rep. 2020 May 5;31(5):107550. doi: 10.1016/j.celrep.2020.107550. Cell Rep. 2020. PMID: 32375028 Free article.
Publisher Correction: Spatial heterogeneity of the T cell receptor repertoire reflects the mutational landscape in lung cancer.
Joshi K, de Massy MR, Ismail M, Reading JL, Uddin I, Woolston A, Hatipoglu E, Oakes T, Rosenthal R, Peacock T, Ronel T, Noursadeghi M, Turati V, Furness AJS, Georgiou A, Wong YNS, Ben Aissa A, Sunderland MW, Jamal-Hanjani M, Veeriah S, Birkbak NJ, Wilson GA, Hiley CT, Ghorani E, Guerra-Assunção JA, Herrero J, Enver T, Hadrup SR, Hackshaw A, Peggs KS, McGranahan N, Swanton C; TRACERx consortium; Quezada SA, Chain B. Joshi K, et al. Nat Med. 2020 Jul;26(7):1148. doi: 10.1038/s41591-020-0866-8. Nat Med. 2020. PMID: 32494063
Publisher Correction: Pulmonary venous circulating tumor cell dissemination before tumor resection and disease relapse.
Chemi F, Rothwell DG, McGranahan N, Gulati S, Abbosh C, Pearce SP, Zhou C, Wilson GA, Jamal-Hanjani M, Birkbak N, Pierce J, Kim CS, Ferdous S, Burt DJ, Slane-Tan D, Gomes F, Moore D, Shah R, Al Bakir M, Hiley C, Veeriah S, Summers Y, Crosbie P, Ward S, Mesquita B, Dynowski M, Biswas D, Tugwood J, Blackhall F, Miller C, Hackshaw A, Brady G, Swanton C, Dive C; TRACERx Consortium. Chemi F, et al. Nat Med. 2020 Jul;26(7):1147. doi: 10.1038/s41591-020-0865-9. Nat Med. 2020. PMID: 32494064
Prospective longitudinal study of immune checkpoint molecule (ICM) expression in immune cell subsets during curative conventional therapy of head and neck squamous cell carcinoma (HNSCC).
von Witzleben A, Fehn A, Grages A, Ezić J, Jeske SS, Puntigam LK, Brunner C, Kraus JM, Kestler HA, Doescher J, Brand M, Theodoraki MN, Ottensmeier CH, Hoffmann TK, Schuler PJ, Laban S. von Witzleben A, et al. Among authors: ottensmeier ch. Int J Cancer. 2021 Apr 15;148(8):2023-2035. doi: 10.1002/ijc.33446. Epub 2020 Dec 30. Int J Cancer. 2021. PMID: 33336372
Determinants of anti-PD-1 response and resistance in clear cell renal cell carcinoma.
Au L, Hatipoglu E, Robert de Massy M, Litchfield K, Beattie G, Rowan A, Schnidrig D, Thompson R, Byrne F, Horswell S, Fotiadis N, Hazell S, Nicol D, Shepherd STC, Fendler A, Mason R, Del Rosario L, Edmonds K, Lingard K, Sarker S, Mangwende M, Carlyle E, Attig J, Joshi K, Uddin I, Becker PD, Sunderland MW, Akarca A, Puccio I, Yang WW, Lund T, Dhillon K, Vasquez MD, Ghorani E, Xu H, Spencer C, López JI, Green A, Mahadeva U, Borg E, Mitchison M, Moore DA, Proctor I, Falzon M, Pickering L, Furness AJS, Reading JL, Salgado R, Marafioti T, Jamal-Hanjani M; PEACE Consortium; Kassiotis G, Chain B, Larkin J, Swanton C, Quezada SA, Turajlic S; TRACERx Renal Consortium. Au L, et al. Cancer Cell. 2021 Nov 8;39(11):1497-1518.e11. doi: 10.1016/j.ccell.2021.10.001. Epub 2021 Oct 28. Cancer Cell. 2021. PMID: 34715028 Free PMC article.
Efficacy outcomes and prognostic factors from real-world patients with advanced non-small-cell lung cancer treated with first-line chemoimmunotherapy: The Spinnaker retrospective study.
Banna GL, Cantale O, Muthuramalingam S, Cave J, Comins C, Cortellini A, Addeo A, Signori A, McKenzie H, Escriu C, Barone G, Chan S, Hicks A, Bainbridge H, Pinato DJ, Ottensmeier C, Gomes F. Banna GL, et al. Int Immunopharmacol. 2022 Sep;110:108985. doi: 10.1016/j.intimp.2022.108985. Epub 2022 Jun 28. Int Immunopharmacol. 2022. PMID: 35777264 Free article.
TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b/3 trial.
Quoix E, Lena H, Losonczy G, Forget F, Chouaid C, Papai Z, Gervais R, Ottensmeier C, Szczesna A, Kazarnowicz A, Beck JT, Westeel V, Felip E, Debieuvre D, Madroszyk A, Adam J, Lacoste G, Tavernaro A, Bastien B, Halluard C, Palanché T, Limacher JM. Quoix E, et al. Lancet Oncol. 2016 Feb;17(2):212-223. doi: 10.1016/S1470-2045(15)00483-0. Epub 2015 Dec 23. Lancet Oncol. 2016. PMID: 26727163 Clinical Trial.
Assessment of neuronal autoantibodies in patients with small cell lung cancer treated with chemotherapy with or without ipilimumab.
Hardy-Werbin M, Arpí O, Taus A, Rocha P, Joseph-Pietras D, Nolan L, Danson S, Griffiths R, Lopez-Botet M, Rovira A, Albanell J, Ottensmeier CH, Arriola E. Hardy-Werbin M, et al. Among authors: ottensmeier ch. Oncoimmunology. 2017 Nov 27;7(2):e1395125. doi: 10.1080/2162402X.2017.1395125. eCollection 2018. Oncoimmunology. 2017. PMID: 29308329 Free PMC article.
CONFIRM: a double-blind, placebo-controlled phase III clinical trial investigating the effect of nivolumab in patients with relapsed mesothelioma: study protocol for a randomised controlled trial.
Fennell DA, Kirkpatrick E, Cozens K, Nye M, Lester J, Hanna G, Steele N, Szlosarek P, Danson S, Lord J, Ottensmeier C, Barnes D, Hill S, Kalevras M, Maishman T, Griffiths G. Fennell DA, et al. Trials. 2018 Apr 18;19(1):233. doi: 10.1186/s13063-018-2602-y. Trials. 2018. PMID: 29669604 Free PMC article.
Recent advances in the molecular landscape of lung neuroendocrine tumors.
Pelosi G, Bianchi F, Hofman P, Pattini L, Ströbel P, Calabrese F, Naheed S, Holden C, Cave J, Bohnenberger H, Dinter H, Harari S, Albini A, Sonzogni A, Papotti M, Volante M, Ottensmeier CH. Pelosi G, et al. Among authors: ottensmeier ch. Expert Rev Mol Diagn. 2019 Apr;19(4):281-297. doi: 10.1080/14737159.2019.1595593. Epub 2019 Mar 27. Expert Rev Mol Diagn. 2019. PMID: 30900485 Review.
Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial.
Fennell DA, Ewings S, Ottensmeier C, Califano R, Hanna GG, Hill K, Danson S, Steele N, Nye M, Johnson L, Lord J, Middleton C, Szlosarek P, Chan S, Gaba A, Darlison L, Wells-Jordan P, Richards C, Poile C, Lester JF, Griffiths G; CONFIRM trial investigators. Fennell DA, et al. Lancet Oncol. 2021 Nov;22(11):1530-1540. doi: 10.1016/S1470-2045(21)00471-X. Epub 2021 Oct 14. Lancet Oncol. 2021. PMID: 34656227 Free PMC article. Clinical Trial.
Ipilimumab in the real world: the UK expanded access programme experience in previously treated advanced melanoma patients.
Ahmad SS, Qian W, Ellis S, Mason E, Khattak MA, Gupta A, Shaw H, Quinton A, Kovarikova J, Thillai K, Rao A, Board R, Nobes J, Dalgleish A, Grumett S, Maraveyas A, Danson S, Talbot T, Harries M, Marples M, Plummer R, Kumar S, Nathan P, Middleton MR, Larkin J, Lorigan P, Wheater M, Ottensmeier CH, Corrie PG. Ahmad SS, et al. Among authors: ottensmeier ch. Melanoma Res. 2015 Oct;25(5):432-42. doi: 10.1097/CMR.0000000000000185. Melanoma Res. 2015. PMID: 26225580 Free PMC article.
SARS-CoV-2 in the abdomen or pelvis: SAFE SURGERY study.
Vimalachandran D, Jones RP, Dickson E, Seehra J, Acheson A, Griffiths EA, Kamarajah S, Leung E, Torrance A, Ottensmeier C, Beggs AD, Whiteside E, Sanna H, Bury D, Youd E, Leopold G, Pugh M, Sundar S, Taylor GS. Vimalachandran D, et al. Br J Surg. 2023 Feb 15;110(3):306-309. doi: 10.1093/bjs/znac297. Br J Surg. 2023. PMID: 36168210 Free PMC article. No abstract available.
A randomised, phase II study of intetumumab, an anti-αv-integrin mAb, alone and with dacarbazine in stage IV melanoma.
O'Day S, Pavlick A, Loquai C, Lawson D, Gutzmer R, Richards J, Schadendorf D, Thompson JA, Gonzalez R, Trefzer U, Mohr P, Ottensmeier C, Chao D, Zhong B, de Boer CJ, Uhlar C, Marshall D, Gore ME, Lang Z, Hait W, Ho P; CNTO 95 Investigators. O'Day S, et al. Br J Cancer. 2011 Jul 26;105(3):346-52. doi: 10.1038/bjc.2011.183. Epub 2011 Jul 12. Br J Cancer. 2011. PMID: 21750555 Free PMC article. Clinical Trial.
Automated Analysis of Proliferating Cells Spatial Organisation Predicts Prognosis in Lung Neuroendocrine Neoplasms.
Bulloni M, Sandrini G, Stacchiotti I, Barberis M, Calabrese F, Carvalho L, Fontanini G, Alì G, Fortarezza F, Hofman P, Hofman V, Kern I, Maiorano E, Maragliano R, Marchiori D, Metovic J, Papotti M, Pezzuto F, Pisa E, Remmelink M, Serio G, Marzullo A, Trabucco SMR, Pennella A, De Palma A, Marulli G, Fassina A, Maffeis V, Nesi G, Naheed S, Rea F, Ottensmeier CH, Sessa F, Uccella S, Pelosi G, Pattini L. Bulloni M, et al. Among authors: ottensmeier ch. Cancers (Basel). 2021 Sep 29;13(19):4875. doi: 10.3390/cancers13194875. Cancers (Basel). 2021. PMID: 34638359 Free PMC article.
Improved survival with ipilimumab in patients with metastatic melanoma.
Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbé C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ. Hodi FS, et al. Among authors: ottensmeier ch. N Engl J Med. 2010 Aug 19;363(8):711-23. doi: 10.1056/NEJMoa1003466. Epub 2010 Jun 5. N Engl J Med. 2010. PMID: 20525992 Free PMC article. Clinical Trial.
INHBA is Enriched in HPV-negative Oropharyngeal Squamous Cell Carcinoma and Promotes Cancer Progression.
Abou Kors T, Hofmann L, Betzler A, Payer K, Bens M, Truong J, von Witzleben A, Thomas J, Kraus JM, Kalaajieh R, Huber D, Ezić J, Benckendorff J, Greve J, Schuler PJ, Ottensmeier CH, Kestler HA, Hoffmann TK, Theodoraki MN, Brunner C, Laban S. Abou Kors T, et al. Among authors: ottensmeier ch. Cancer Res Commun. 2024 Feb 28;4(2):571-587. doi: 10.1158/2767-9764.CRC-23-0258. Cancer Res Commun. 2024. PMID: 38329386 Free PMC article.
Adaptive clinical trial of AZD7442 and SARS-CoV-2 vaccination in immunosuppressed patients highly vulnerable to infection with SARS-CoV-2 virus (RAPID-PROTECTION): protocol for a multicentre, interventional open-label, randomised controlled trial.
Varley M, Euden J, Adams R, Barnes E, Bodman C, Choy E, Cicconi P, Dagley V, Ewer K, Griffin S, Harris D, Hill A, Hood K, Knapper S, Pringle S, Porter C, Ottensmeier CH, Raisanen L, Ray R, Tangney R, Wilson K, Nixon LS, Thomas-Jones E, Tuthill M. Varley M, et al. Among authors: ottensmeier ch. BMJ Open. 2025 Jan 20;15(1):e084345. doi: 10.1136/bmjopen-2024-084345. BMJ Open. 2025. PMID: 39832967 Free PMC article.
Subgroup analyses of the phase 3 FOCUS study of melphalan/hepatic delivery system in patients with unresectable metastatic uveal melanoma.
Zager JS, Orloff M, Ferrucci PF, Choi J, Eschelman DJ, Glazer ES, Ejaz A, Richtig E, Ochsenreither S, Reddy SA, Lowe MC, Beasley GM, Gesierich A, Gschnell M, Dummer R, Arance A, Fenwick SW, Sacco JJ, John J, Wheater M, Ottensmeier CH. Zager JS, et al. Among authors: ottensmeier ch. J Cancer Res Clin Oncol. 2025 Dec 29;152(1):25. doi: 10.1007/s00432-025-06291-x. J Cancer Res Clin Oncol. 2025. PMID: 41461960 Free PMC article. Clinical Trial.
An Open-label, Randomized Study of Melphalan/Hepatic Delivery System Versus Best Alternative Care in Patients with Unresectable Metastatic Uveal Melanoma.
Zager JS, Orloff M, Ferrucci PF, Choi J, Eschelman DJ, Glazer ES, Ejaz A, Howard JH, Richtig E, Ochsenreither S, Reddy SA, Lowe MC, Beasley GM, Gesierich A, Bender A, Gschnell M, Dummer R, Rivoire M, Arance A, Fenwick SW, Sacco JJ, Haferkamp S, Weishaupt C, John J, Wheater M, Ottensmeier CH. Zager JS, et al. Among authors: ottensmeier ch. Ann Surg Oncol. 2025 Jul;32(7):4976-4988. doi: 10.1245/s10434-025-17231-x. Epub 2025 Apr 7. Ann Surg Oncol. 2025. PMID: 40192993 Free PMC article. Clinical Trial.
Immune checkpoint expression on tumor-infiltrating lymphocytes (TIL) is dependent on HPV status in oropharyngeal carcinoma (OPSCC) - A single-cell RNA sequencing analysis.
von Witzleben A, Grages A, Thomas J, Ezić J, Brunner C, Schuler PJ, Kraus JM, Kestler HA, Vahl JM, Doescher J, King EV, Ottensmeier CH, Hoffmann TK, Laban S. von Witzleben A, et al. Among authors: ottensmeier ch. Oral Oncol. 2024 Dec;159:107107. doi: 10.1016/j.oraloncology.2024.107107. Epub 2024 Nov 15. Oral Oncol. 2024. PMID: 39549431 Free article.
Correction: Efficacy and Safety of the Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma: Results from an Open-Label, Single-Arm, Multicenter Phase 3 Study.
Zager JS, Orloff M, Ferrucci PF, Choi J, Eschelman DJ, Glazer ES, Ejaz A, Howard JH, Richtig E, Ochsenreither S, Reddy SA, Lowe MC, Beasley GM, Gesierich A, Bender A, Gschnell M, Dummer R, Rivoire M, Arance A, Fenwick SW, Sacco JJ, Haferkamp S, Weishaupt C, John J, Wheater M, Ottensmeier CH. Zager JS, et al. Among authors: ottensmeier ch. Ann Surg Oncol. 2024 Nov;31(12):8262-8263. doi: 10.1245/s10434-024-15886-6. Ann Surg Oncol. 2024. PMID: 39026142 Free PMC article. No abstract available.
Efficacy and Safety of the Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma: Results from an Open-Label, Single-Arm, Multicenter Phase 3 Study.
Zager JS, Orloff M, Ferrucci PF, Choi J, Eschelman DJ, Glazer ES, Ejaz A, Howard JH, Richtig E, Ochsenreither S, Reddy SA, Lowe MC, Beasley GM, Gesierich A, Bender A, Gschnell M, Dummer R, Rivoire M, Arance A, Fenwick SW, Sacco JJ, Haferkamp S, Weishaupt C, John J, Wheater M, Ottensmeier CH. Zager JS, et al. Among authors: ottensmeier ch. Ann Surg Oncol. 2024 Aug;31(8):5340-5351. doi: 10.1245/s10434-024-15293-x. Epub 2024 May 4. Ann Surg Oncol. 2024. PMID: 38704501 Free PMC article. Clinical Trial.
The Neo-Open Reading Frame Peptides That Comprise the Tumor Framome Are a Rich Source of Neoantigens for Cancer Immunotherapy.
Martin MV, Aguilar-Rosas S, Franke K, Pieterse M, Langelaar JV, Schreurs R, Bijlsma MF, Besselink MG, Koster J, Timens W, Khasraw M, Ashley DM, Keir ST, Ottensmeier CH, King EV, Verheij J, Waasdorp C, Valk PJM, Engels SAG, Oostenbach E, van Dinter JT, Hofman DA, Mok JY, van Esch WJE, Wilmink H, Monkhorst K, Verheul HMW, Poel D, Hiltermann TJN, Kempen LCLTV, Groen HJM, Aerts JGJV, Heesch SV, Löwenberg B, Plasterk R, Kloosterman WP. Martin MV, et al. Among authors: ottensmeier ch. Cancer Immunol Res. 2024 Jun 4;12(6):759-778. doi: 10.1158/2326-6066.CIR-23-0158. Cancer Immunol Res. 2024. PMID: 38573707
Intra-tumoral T cells in pediatric brain tumors display clonal expansion and effector properties.
Upadhye A, Meza Landeros KE, Ramírez-Suástegui C, Schmiedel BJ, Woo E, Chee SJ, Malicki D, Coufal NG, Gonda D, Levy ML, Greenbaum JA, Seumois G, Crawford J, Roberts WD, Schoenberger SP, Cheroutre H, Ottensmeier CH, Vijayanand P, Ganesan AP. Upadhye A, et al. Among authors: ottensmeier ch. Nat Cancer. 2024 May;5(5):791-807. doi: 10.1038/s43018-023-00706-9. Epub 2024 Jan 16. Nat Cancer. 2024. PMID: 38228835 Free PMC article.
Melanoma-reactive T cells take up residence.
Ganesan AP, Ottensmeier CHH. Ganesan AP, et al. Nat Cancer. 2021 Mar;2(3):253-255. doi: 10.1038/s43018-021-00189-6. Nat Cancer. 2021. PMID: 35121962 Free PMC article.
Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial.
Corrie PG, Marshall A, Nathan PD, Lorigan P, Gore M, Tahir S, Faust G, Kelly CG, Marples M, Danson SJ, Marshall E, Houston SJ, Board RE, Waterston AM, Nobes JP, Harries M, Kumar S, Goodman A, Dalgleish A, Martin-Clavijo A, Westwell S, Casasola R, Chao D, Maraveyas A, Patel PM, Ottensmeier CH, Farrugia D, Humphreys A, Eccles B, Young G, Barker EO, Harman C, Weiss M, Myers KA, Chhabra A, Rodwell SH, Dunn JA, Middleton MR. Corrie PG, et al. Among authors: ottensmeier ch. Ann Oncol. 2019 Dec 1;30(12):2013-2014. doi: 10.1093/annonc/mdz237. Ann Oncol. 2019. PMID: 31430371 Free PMC article. No abstract available.
DOC-MEK: a double-blind randomized phase II trial of docetaxel with or without selumetinib in wild-type BRAF advanced melanoma.
Gupta A, Love S, Schuh A, Shanyinde M, Larkin JM, Plummer R, Nathan PD, Danson S, Ottensmeier CH, Lorigan P, Collins L, Wise A, Asher R, Lisle R, Middleton MR. Gupta A, et al. Among authors: ottensmeier ch. Ann Oncol. 2014 May;25(5):968-74. doi: 10.1093/annonc/mdu054. Epub 2014 Feb 24. Ann Oncol. 2014. PMID: 24567366 Free article. Clinical Trial.
Tumour-infiltrating lymphocytes predict for outcome in HPV-positive oropharyngeal cancer.
Ward MJ, Thirdborough SM, Mellows T, Riley C, Harris S, Suchak K, Webb A, Hampton C, Patel NN, Randall CJ, Cox HJ, Jogai S, Primrose J, Piper K, Ottensmeier CH, King EV, Thomas GJ. Ward MJ, et al. Among authors: ottensmeier ch. Br J Cancer. 2014 Jan 21;110(2):489-500. doi: 10.1038/bjc.2013.639. Epub 2013 Oct 29. Br J Cancer. 2014. PMID: 24169344 Free PMC article.